University of Texas/Texas AM Investment Management Co (UTIMCO)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.89M Buy
+33,065
New +$1.81M 0.22% 67
2026
Q1
Sell
-41,928
Closed -$2.49M 311
2025
Q4
$2.49M Buy
+41,928
New +$2.28M 0.35% 54
2024
Q4
Sell
-10,213
Closed -$718K 176
2024
Q3
$718K Buy
10,213
+1,080
+12% +$90.3K 0.12% 73
2024
Q2
$752K Sell
9,133
-5,567
-38% -$463K 0.15% 73
2024
Q1
$1.28M Buy
+14,700
New +$1.32M 0.27% 57

Other funds holding BMRN

University of Texas/Texas AM Investment Management Co (UTIMCO)'s BMRN Position: Q2 2026 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 33,065 shares worth $1.89M. The stake represents 0.22% of the portfolio and ranks #67 among its holdings. This is a return to the name: University of Texas/Texas AM Investment Management Co (UTIMCO) previously reported a position in BMRN as recently as Q4 2025.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in BMRN in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.49M in Q4 2025. 356 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • University of Texas/Texas AM Investment Management Co (UTIMCO) held 33,065 shares of BioMarin Pharmaceuticals worth $1.89M as of Q2 2026.
  • BioMarin Pharmaceuticals was a new University of Texas/Texas AM Investment Management Co (UTIMCO) position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.22% of University of Texas/Texas AM Investment Management Co (UTIMCO)'s portfolio in Q2 2026, its #67 holding.
  • University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in BioMarin Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
  • University of Texas/Texas AM Investment Management Co (UTIMCO)'s BioMarin Pharmaceuticals position peaked at $2.49M in Q4 2025.
  • 356 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q2 2026, filed 3 Aug 2026.